Opsonophagocytic and bactericidal activity mediated by purified IgG subclass antibodies after vaccination with the Norwegian group B meningococcal vaccine

Scandinavian Journal of Immunology

Volumn 47, Issue 4, 1998, Pages 388-396

  Aase, A ^a   Hoiby E A ^a   Michaelsen, T E ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; MENINGOCOCCUS VACCINE;

ANTIBODY RESPONSE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; NEUTROPHIL; NORMAL HUMAN; OPSONIZATION; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VACCINATION;

EID: 0031955447     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1998.00319.x     Document Type: Article

References (32)

1. Buckley RH. Primary immunodeficiency diseases. In: Paul WE, ed. Fundamental Immunology. New York: Raven Press, 1993;1353-74.
2. Garred P, Michaelsen TE, Aase A. The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scand J Immunol 1989;30:379-82.
3. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991;21:11-6.
4. Bruggemann M, Williams GT, Bindon CI et al. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies. J Exp Med 1987;166:1351-61.
5. Bindon CI, Hale G, Bruggemann M. Waldmann H. Human monoclonal IgG isotypes differ in complement activating function at the level of C4 as well as Clq. J Exp Med 1988;168:127-42.
6. Walker MR, Woof JM, Bruggemann M, Jefferis R, Burton DR. Interaction of human IgG chimeric antibodies with the human FcRI and FcRII receptors: requirements for antibody-mediated host cell-target cell interaction. Mol Immunol 1989;26:403-11.
7. Michaelsen TE, Aase A, Norderhaug L, Sandlie I. Antibody dependent cell-mediated cytotoxicity induced by chimeric mouse-human IgG subclasses and IgG3 antibodies with altered hinge region. Mol Immunol 1992;29:319-26.
8. Aase A, Michaelsen TE. Opsonophagocytic activity induced by chimeric antibodies of the four human IgG subclasses with or without help from complement. Scand J Immunol 1994;39:581-7.
9. Lortan JE, Kaniuk AS, Monteil MA. Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults. Clin Exp Immunol 1993;91:54-7.
10. Bredius RG, de Vries CE, Troelstra A et al. Phagocytosis of Staphylococcus aureus and Haemophilus influenzae type b opsonized with polyclonal human IgG1 and lgG2 antibodies. Functional hFc gamma RIIa polymorphism to IgG2. J Immunol 1993;151:1463-72.
11. Amir J, Scott MG, Nahm MH, Granoff DM. Bactericidal and opsonic activity of IgG1 and IgG2 anticapsular antibodies to Haemophilus influenzae type b. J Infect Dis 1990;162:163-71.
12. Weinberg GA, Granoff DM, Nahm MH, Shackelford PG. Functional activity of different IgG subclass antibodies against type b capsular polysaccharide of Haemophilus influenzae. J Immunol 1986;136:4232-6.
13. Bredius RG, Driedijk PC, Schouten MF, Weening RS, Out TA. Complement activation by polyclonal immunoglobulin G1 and G2 antibodies against Staphylococcus aureus, Haemophilus influenzae type b, and tetanus toxoid. Infect Immun 1992;60:4838-47.
14. van de Winkel JG, Capel PJ. Human IgG Fc receptor heterogeneity: molecular aspects and clinical implications. Immunol Today 1993;14:215-21.
15. Wedege E, Michaelsen TE. Human immunoglobulin G subclass immune response to outer membrane antigens in meningococcal group B vaccine. J Clin Microbiol 1987;25:1349-53.
16. Sjursen H, Wedege E, Rosenqvist E et al. IgG subclass antibodies to serogroup B meningococcal outer membrane antigens following infection and vaccination. APMIS 1990;98:1061-9.
17. Næss LM, Aarvak T, Aase A et al. Human IgG subclass response in relation to bactericidal and opsonic activity after immunization with three doses of the Norwegian serogroup B meningococcal outer membrane vaccine. Submitted.
18. Rosenqvist E, Høiby EA, Wedege E, Kusecek B, Achtman M. The 5C protein of Neisseria meningitidis is highly immunogenic in humans and induces bactericidal antibodies. J Infect Dis 1993;167:1065-73.
19. Fredriksen JH, Rosenqvist E, Wedege E et al. Production, characterization and control of MenB-vaccine 'Folkehelsa': an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991;14:67-80.
20. Jefferis J, Weston PD, Stanworth DR. Relationship between the papain sensitivity of human γG immunoglobulins and their heavy chain subclass. Nature 1968;219:646-9.
21. Falconer AE, Carson R, Johnstone R, Bird P, Kehoe M, Calvert JE. Distinct IgG1 and IgG3 subclass responses to two streptococcal protein antigens in man: analysis of antibodies to streptolysin O and M protein using standardized subclass-specific enzyme-linked immunosorbent assays. Immunology 1993;79:89-94.
22. Næss LM, Rosenqvist E, Høiby EA, Michaelsen TE. Quantitation of IgG subclass antibody responses after immunization with a group B meningococcal outer membrane vesicle vaccine, using monoclonal mouse-human chimeric antibodies as standards. J Immunol Methods 1996;196:41-9.
23. Rosenqvist E, Høiby EA, Wedege E et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995;63:4642-52.
24. Halstensen A, Haneberg B. Standardization of a chemiluminescence method for the measurement of meningococcal opsonins using ethanol-fixed meningococci. Acta Pathol Microbiol Immunol Scand (C) 1987;95:155-60.
25. Gaarder PI, Natvig J. Hidden rheumatoid factors reacting with 'non a' and other antigens of native autologous IgG. J Immunol 1970;105:928-35.
26. Aase A, Bjune G, Høiby EA, Rosenqvist E, Pedersen AK, Michaelsen TE. Comparison among opsonic activity, amimeningococcal immunoglobulin G response, and serum bactericidal activity against meningococci in sera from vaccinees after immunization with a serogroup B outer membrane vesicle vaccine. Infect Immun 1995;63:3531-6.
27. Warmerdam PA, van de Winkel JG, Vlug A, Westerdaal NA, Capel PJA. A single amino acid in the second Ig-like domain of the human Fc gamma receptor II is critical for human IgG2 binding. J Immunol 1991;147:1338-43.
28. Høiby EA, Rosenqvist E, Frøholm LO et al. Bactericidal antibodies after vaccination with the Norwegian meningococcal serogroup B outer membrane vesicle vaccine: a brief survey. NIPH Ann 1991;14:147-56.
29. Perkins B, Jonsdottir K, Briem H et al. Immunogenicity of two efficacious outer membrane protein-based serogroup B meningococcal vaccines among young adults in Iceland. J Infect Dis 1998: in press.
30. Wedege E, Frøholm LO. Human antibody response to a group B serotype 2a meningococcal vaccine determined by immunoblotting. Infect Immun 1986;51:571-8.
31. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practise of Infectious Diseases, 4th edn. New York: Churchill Livingstone, 1995:1811-26.
32. Brandtzaeg P. Pathogenesis of meningococcal infections. In: Cartwright K, ed. Meningococcal Disease. New York: John Wiley & Sons Ltd, 1995:71-114.